Targeting CD73 and correcting adenosinergic signaling in critically ill patients

Area of Science:

• Biochemistry
• Immunology
• Critical Care Medicine

Background:

• Intensive care units (ICUs) are vital for critically ill patients, often experiencing systemic inflammation and multi-organ injury.
• Current therapeutic options for critical illness complications are limited, with no FDA-approved drugs specifically for these conditions.
• Cellular damage releases damage-associated molecular patterns (DAMPs), such as extracellular adenosine triphosphate (eATP), contributing to inflammation.

Purpose of the Study:

• To investigate the therapeutic potential of modulating ectonucleotidases, like CD73 and CD39, in critical illness.
• To explore the role of extracellular nucleotide metabolism in systemic inflammation and organ injury.
• To determine if targeting adenosine generation or nucleotide scavenging offers survival benefits in critical care settings.

Main Methods:

• Review of existing literature on ectonucleotidases (CD73, CD39) in critical illness models.
• Analysis of the impact of CD73 boosting on survival and hospital/ICU stay.
• Discussion of upcoming pre-clinical studies evaluating soluble CD39 for eATP hydrolysis in sepsis and post-cardiac surgery.

Main Results:

• Pharmacological boosting of CD73 has demonstrated survival benefits and reduced hospital and ICU lengths of stay in critically ill patients.
• Extracellular adenosine triphosphate (eATP) is implicated as a DAMP contributing to inflammation and organ injury.
• The precise benefit of scavenging eATP versus generating adenosine in inflammatory diseases requires further investigation.

Conclusions:

• Modulating ectonucleotidases, including CD39 and CD73, presents a potential therapeutic strategy for critically ill patients.
• Exogenous administration of CD39, CD73, or other ectonucleotidases may offer significant clinical benefits.
• Targeting extracellular nucleotide metabolism holds promise for improving outcomes in critical care medicine.